Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo

Jakub Golab, Radoslaw Zagozdzon, Katarzyna Kozar, Rafal Kaminski, Adam Giermasz, Tomasz Stoklosa, Witold Lasek, Marek Jakóbisiak

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In previous studies we have shown that combined chemo-immunotherapy of L1210 leukemia with IL-12 and doxorubicin results in striking anti-tumor effects producing 100% of long-term survivors. In this study we investigated the efficacy of a combination of IL-12 and mitoxantrone in murine L1210 leukemia. Mice inoculated with 1×105 leukemia cells were treated with a single dose of mitoxantrone and seven daily doses of IL-12, and were daily observed for survival. Treatment with IL-12 or mitoxantrone given alone produced moderate anti-leukemic effects. However, combination of both drugs resulted in a significant prolongation of mouse survival time. Importantly, there were almost 50% of long-term (>60 days) survivors among the mice treated with both agents. This therapeutic effect was completely abrogated by sub-lethal, whole-body X-irradiation, and significantly reduced after macrophage depletion.

Original languageEnglish (US)
Pages (from-to)177-181
Number of pages5
JournalOncology Reports
Volume7
Issue number1
StatePublished - 2000
Externally publishedYes

Fingerprint

Leukemia L1210
Mitoxantrone
Interleukin-12
Survivors
Neoplasms
Whole-Body Irradiation
Therapeutic Uses
Drug Combinations
Therapeutics
Immunotherapy
Doxorubicin
Leukemia
Macrophages
Survival

Keywords

  • Chemoimmunotherapy
  • Interleukin-12
  • L1210 leukemia
  • Macrophages
  • Mitoxantrone

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Golab, J., Zagozdzon, R., Kozar, K., Kaminski, R., Giermasz, A., Stoklosa, T., ... Jakóbisiak, M. (2000). Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo. Oncology Reports, 7(1), 177-181.

Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo. / Golab, Jakub; Zagozdzon, Radoslaw; Kozar, Katarzyna; Kaminski, Rafal; Giermasz, Adam; Stoklosa, Tomasz; Lasek, Witold; Jakóbisiak, Marek.

In: Oncology Reports, Vol. 7, No. 1, 2000, p. 177-181.

Research output: Contribution to journalArticle

Golab, J, Zagozdzon, R, Kozar, K, Kaminski, R, Giermasz, A, Stoklosa, T, Lasek, W & Jakóbisiak, M 2000, 'Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo', Oncology Reports, vol. 7, no. 1, pp. 177-181.
Golab, Jakub ; Zagozdzon, Radoslaw ; Kozar, Katarzyna ; Kaminski, Rafal ; Giermasz, Adam ; Stoklosa, Tomasz ; Lasek, Witold ; Jakóbisiak, Marek. / Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo. In: Oncology Reports. 2000 ; Vol. 7, No. 1. pp. 177-181.
@article{ca6af86421d54a349938f884662ae5e4,
title = "Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo",
abstract = "In previous studies we have shown that combined chemo-immunotherapy of L1210 leukemia with IL-12 and doxorubicin results in striking anti-tumor effects producing 100{\%} of long-term survivors. In this study we investigated the efficacy of a combination of IL-12 and mitoxantrone in murine L1210 leukemia. Mice inoculated with 1×105 leukemia cells were treated with a single dose of mitoxantrone and seven daily doses of IL-12, and were daily observed for survival. Treatment with IL-12 or mitoxantrone given alone produced moderate anti-leukemic effects. However, combination of both drugs resulted in a significant prolongation of mouse survival time. Importantly, there were almost 50{\%} of long-term (>60 days) survivors among the mice treated with both agents. This therapeutic effect was completely abrogated by sub-lethal, whole-body X-irradiation, and significantly reduced after macrophage depletion.",
keywords = "Chemoimmunotherapy, Interleukin-12, L1210 leukemia, Macrophages, Mitoxantrone",
author = "Jakub Golab and Radoslaw Zagozdzon and Katarzyna Kozar and Rafal Kaminski and Adam Giermasz and Tomasz Stoklosa and Witold Lasek and Marek Jak{\'o}bisiak",
year = "2000",
language = "English (US)",
volume = "7",
pages = "177--181",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "1",

}

TY - JOUR

T1 - Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo

AU - Golab, Jakub

AU - Zagozdzon, Radoslaw

AU - Kozar, Katarzyna

AU - Kaminski, Rafal

AU - Giermasz, Adam

AU - Stoklosa, Tomasz

AU - Lasek, Witold

AU - Jakóbisiak, Marek

PY - 2000

Y1 - 2000

N2 - In previous studies we have shown that combined chemo-immunotherapy of L1210 leukemia with IL-12 and doxorubicin results in striking anti-tumor effects producing 100% of long-term survivors. In this study we investigated the efficacy of a combination of IL-12 and mitoxantrone in murine L1210 leukemia. Mice inoculated with 1×105 leukemia cells were treated with a single dose of mitoxantrone and seven daily doses of IL-12, and were daily observed for survival. Treatment with IL-12 or mitoxantrone given alone produced moderate anti-leukemic effects. However, combination of both drugs resulted in a significant prolongation of mouse survival time. Importantly, there were almost 50% of long-term (>60 days) survivors among the mice treated with both agents. This therapeutic effect was completely abrogated by sub-lethal, whole-body X-irradiation, and significantly reduced after macrophage depletion.

AB - In previous studies we have shown that combined chemo-immunotherapy of L1210 leukemia with IL-12 and doxorubicin results in striking anti-tumor effects producing 100% of long-term survivors. In this study we investigated the efficacy of a combination of IL-12 and mitoxantrone in murine L1210 leukemia. Mice inoculated with 1×105 leukemia cells were treated with a single dose of mitoxantrone and seven daily doses of IL-12, and were daily observed for survival. Treatment with IL-12 or mitoxantrone given alone produced moderate anti-leukemic effects. However, combination of both drugs resulted in a significant prolongation of mouse survival time. Importantly, there were almost 50% of long-term (>60 days) survivors among the mice treated with both agents. This therapeutic effect was completely abrogated by sub-lethal, whole-body X-irradiation, and significantly reduced after macrophage depletion.

KW - Chemoimmunotherapy

KW - Interleukin-12

KW - L1210 leukemia

KW - Macrophages

KW - Mitoxantrone

UR - http://www.scopus.com/inward/record.url?scp=0033631317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033631317&partnerID=8YFLogxK

M3 - Article

C2 - 10601614

AN - SCOPUS:0033631317

VL - 7

SP - 177

EP - 181

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 1

ER -